NCT04478227 - TPO-Mimetic Use in Children for Hematopoietic Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2020

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions

Bone Marrow Failure DisordersAplastic AnemiaThrombocytopeniaRefractory Cytopenia of ChildhoodMyelodysplastic Syndrome(MDS)

Interventions

DRUG

Romiplostim

Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Trial Locations (1)

52242

University of Iowa Hospitals & Clinics, Iowa City